Shanghai Fosun Pharmaceutical Group Co Ltd (600196) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others.
Total Assets Chart for Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) total assets for FY2025 were CNY 120.5B, a 2.6% change from FY2024. Shanghai Fosun Pharmaceutical Group Co Ltd's total assets grew from CNY 106.7M in 1995 to CNY 120.5B in 2025 (112805.2% over 30 years). Total assets compound annual growth rate: 5-year CAGR of 7.6%, 10-year CAGR of 12.2%, 20-year CAGR of 16.5%.
Total Assets (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥61.77B
- Implied Share Price
- ¥29.16
- Enterprise Value
- ¥82.32B
- Revenue (TTM)
- ¥42.59B
- EBITDA
- ¥5.90B
- Profit Margin
- 7.96%
- Trailing P/E
- 18.07
- Forward P/E
- 17.76
- Price/Book (MRQ)
- 1.27
- Price/Sales (TTM)
- 1.45
- EV/EBITDA
- 8.35
- EV/Revenue
- 1.93
- Dividend Yield
- 1.69%
- Book Value
- ¥18.46
- Free Cash Flow (FY2025)
- ¥1.56B
- Free Cash Flow Yield
- 2.52%
Snapshot as of 23rd September 2026 — not point-in-time controlled, may lag the live market by a few days.